Opendata, web and dolomites

MeningoSpeed SIGNED

A unique cost-effective and point of care (PoC) kit for the non-invasive rapid in vitro diagnosis of meningococcal disease

Total Cost €


EC-Contrib. €






 MeningoSpeed project word cloud

Explore the words cloud of the MeningoSpeed project. It provides you a very rough idea of what is the project "MeningoSpeed" about.

meningococcal    meningospeed    core    33    md    profitable    pasteur    plan    reducing    latex    financial    nm    disruptive    commercial    meningitidis    net    opportunity    lt    hospital    gt    lethality    deaths    cagr    gold    faster    treatment    ca    technological    diagnosis    serogroups    agglutination    healthcare    market    vs    3h    rapid    patients    added    least    societal    vast    acute    finalize    epidemic    diseases    care    business    burden    performance    cheaper    savings    six    immunochromatographic    accumulated    spin    successful    diagnostic    annually    abcxwy    solution    neisseria    million    infectious    25    company    caused    permanent    15    france    point    direct    disease    accuracy    alternatives    min    launch    unmet    valued    tools    mainly    source    despite    people    off    68    worldwide    projected    fashion    limited    demonstrated    93    young    vitro    capability    monitoring    children    competitive    biospeedia    nanoparticle    sensitivity    45    tests    purchasers    profit    first    pcr    feasibility    10    health    2026    specificity    lack    physicians    invasive    2022    accurate    costly    secure    public    sequelae    tool   

Project "MeningoSpeed" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 75724
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOSPEEDIA FR (PARIS) coordinator 50˙000.00


 Project objective

Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MENINGOSPEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MENINGOSPEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)


Read More